1.	Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AZA-MDS-001, NCT01201811
2.	Phase II/III Chemotherapy with DNM/ARA-C Induction and DNM/ARA-C/TG, DNM/AZC, and ARA-C/TG Maintenance for Acute Myelogenous Leukemia Phase: Phase III, Phase II Type: Treatment Status: Completed Age: under 60 Sponsor: Protocol IDs: NCI-D81-018-590, DFCI-80035
3.	Phase II/III Combination Chemotherapy with AMSA/AZC or AMSA/VP-16 for Acute Nonlymphocytic Leukemia Refractory to Standard Therapy Phase: Phase III, Phase II Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: NCI-D82-013-686
4.	Phase II/III Consolidation Chemotherapy with VP-16/AMSA/AZC Following Induction with DNM/ARA-C/TG for Adult Primary or Secondary Leukemia Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: NCI-D82-051-605
5.	Phase II/III Pilot Study of Induction and Intensification Chemotherapy with VP-16, ARA-C, DNR, 5-AZ, and m-AMSA, Using "Modelled" Plasma Drug Concentrations of VP-16 and ARA-C, in Children with Acute Nonlymphocytic Leukemia Phase: Phase III, Phase II Type: Treatment Status: Completed Age: under 21 Sponsor: NCI Protocol IDs: SJCRH-AML-87, NCI-T86-0203D, T86-0203
6.	Phase II/III Randomized Comparison of VP-16/AMSA vs VP-16/AMSA/AZC in Children with Refractory ANLL (Summary Last Modified 10/91) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 21 and under Sponsor: NCI Protocol IDs: POG-8820
7.	Phase I/III Induction with ADR/ARA-C/VCR/PRDL and Consolidation and Maintenance with ADR/ARA-C, ADR/AZC, MePRDL/VCR/6-MP/MTX, or ARA-C for ANLL Phase: Phase III, Phase I Type: Treatment Status: Closed Age: under 50 Sponsor: Protocol IDs: DFCI-76006, DFCI-VAPA-10
8.	Phase III Randomized Study of Subcutaneous Azacytidine vs Observation in Myelodysplastic Syndrome Phase: Phase III Type: Treatment Status: Closed Age: over 15 Sponsor: NCI Protocol IDs: CLB-9221, CALGB-9221
9.	Phase III Therapy with DNM, ARA-C, AZC, Beta-TGDR, TG & BCG for Induction, Consolidation & Maintenance of Acute Myelogenous Leukemia (Summary Last Modified 04/97) Phase: Phase III Type: Treatment Status: Completed Age: 15 and over Sponsor: Protocol IDs: SEG-77AML318, SEG-77AML0103
10.	Chemotherapy with TAD (6-TG/ARA-C/DNM), ADR, AZC plus Immunotherapy with C. parvum, Allogeneic Leukemic Blasts for Acute Myelogenous Leukemia Phase: Phase III Type: Treatment Status: Closed Age: 3 and over Sponsor: Protocol IDs: UCLA-ALP-3
11.	Phase III Study of Dzapo Chemotherapy Plus TG/AZC/ARA-C/VCR with or without Immunotherapy for Acute Myelogenous Leukemia in Children Phase: Phase III Type: Treatment Status: Closed Age: under 20 Sponsor: NCI Protocol IDs: CCG-241
12.	Phase III Intensive AZA/AMSA plus ARA-C Consolidation and Intensive AZA/AMSA Maintenance Following DAT (DNM/ARA-C/6-TG) Induction for Previously Untreated Adult ANLL Phase: Phase III Type: Treatment Status: Closed Age: 15 to 70 Sponsor: Protocol IDs: NCI-D82-061-724
13.	Phase III Two Intense Consolidation Regimens without Maintenance vs Standard Consolidation plus Standard Maintenance vs Bone Marrow Transplantation in Adult ANLL Phase: Phase III Type: Treatment Status: Closed Age: 15 to 50 Sponsor: Protocol IDs: SEG-AML-81312R
14.	Phase III Comparison of ARA-C/DNM/TG vs ARA-C/VCR/DM for Remission Induction plus Intensive Multi-Drug Maintenance for Previously Untreated Pediatric ANLL Phase: Phase III Type: Treatment Status: Completed Age: 21 and under Sponsor: NCI Protocol IDs: POG-8101, POG-ANLL-2
15.	Phase III Chemotherapy with High-Dose ARA-C/DNM Followed by VP-16/AZC as Induction and VP-16/AZC Alternating with High-Dose ARA-C/DNM as Maintenance for Childhood AML (Summary Last Modified 04/88) Phase: Phase III Type: Treatment Status: Completed Age: under 18 Sponsor: NCI Protocol IDs: DFCI-84010, NCI-T84-0245D, T84-0245
16.	Phase III Cyclic Maintenance with AMSA/ARA-C and AMSA/AZC vs Maintenance with DNM/VCR/ARA-C after Remission Induction with DNM/VCR/ARA-C in ANLL Phase: Phase III Type: Treatment Status: Closed Age: 10 to 65 Sponsor: Protocol IDs: EORTC-06821
17.	Phase III Randomized Comparison of Induction with Denver Therapy (VP-16/DNM/ARA-C/TG/DM) vs "7 + 3" Therapy (DNM/ARA-C) and of Maintenance Chemotherapy vs No Maintenance Therapy in Previously Untreated Children with ANLL Phase: Phase III Type: Treatment Status: Completed Age: 0 to 21 Sponsor: NCI Protocol IDs: CCG-213
18.	Phase III Randomized Trial of Chemotherapy with DAT (DNR/ARA-C/TG) Given in a 1 plus 5 vs 3 plus 10 Schedule as Induction Therapy, COAP (CTX/VCR/ARA-C/PRED) vs MAZE (AMSA/AZA/VP-16) as Consolidation Therapy, and ARA-C/TG plus COAP as Maintenance Therapy vs No Maintenance Therapy in Adults with Acute Myeloid Leukemia (Summary Last Modified 06/97) Phase: Phase III Type: Treatment Status: Completed Age: any age Sponsor: NCI Protocol IDs: UKM-MRC-AML-9, NCI-T83-1410Q, T83-1410
19.	Phase III Induction plus Early and Late Intensification Chemotherapy for Previously Untreated AML Phase: Phase III Type: Treatment Status: Closed Age: under 21 Sponsor: Protocol IDs: NCI-D81-011-693, HOG-8130
20.	Phase III Combination Chemotherapy (Cyclic vs Continuous) vs Bone Marrow Transplantation in Previously Untreated Pediatric ALL Phase: Phase III Type: Treatment Status: Completed Age: 21 and under Sponsor: NCI Protocol IDs: CCG-251
21.	Phase III Randomized Study of Extended Chemotherapy Using Non-Cross Resistant Drug Combinations vs Abbreviated Chemotherapy Followed by Autologous Bone Marrow Therapy in Children with AML Phase: Phase III Type: Treatment Status: Completed Age: 21 and under Sponsor: NCI Protocol IDs: POG-8821, POG-8821/22
22.	Phase III Intensive Sequential ADR/ARA-C, VP-16/AZC, 6-TG/ARA-C, and ADR/ARA-C vs Allogenic Bone Marrow Transplantation After Induction with DNM/ARA-C for Childhood Acute Nonlymphocytic Leukemia Phase: Phase III Type: Treatment Status: Closed Age: under 20 Sponsor: Protocol IDs: NCI-D82-050-308, SJCRH-AML-80
23.	A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AZA PH GL 2003 CL 001, NCT00071799
24.	Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) Phase: Phase III Type: Treatment Status: Completed Age: 18 to 120 Sponsor: Other Protocol IDs: TUD-RELAZA-008, 2006-001040-31 (EudraCT Nr.), NCT00422890
25.	Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) Phase: Phase III Type: Treatment Status: Closed Age: 65 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AZA-AML-001, NCT01074047